Innate Pharma Dirección

Dirección controles de criterios 4/4

El CEO de Innate Pharma's es Herve Brailly, nombrado en Jan 1999, tiene una permanencia de 25.25 años. posee directamente un 0.92% de las acciones de la empresa, con un valor de €1.61M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 5.4 años, respectivamente.

Información clave

Herve Brailly

Chief Executive Officer (CEO)

€100.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	25.4yrs
Participación del CEO	0.9%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Herve Brailly (63 yo)

25.4yrs

Permanencia

€100,000

Compensación

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Herve Brailly	Co-Founder	25.4yrs	€100.00k	0.92% € 1.9m
Yannis Morel	Executive VP	9.1yrs	€599.92k	0.24% € 492.3k
François Romagné	Founder	no data	sin datos	sin datos
Eric Vivier	Founder	6.4yrs	sin datos	0.26% € 532.9k
Marc Bonneville	Founder	no data	sin datos	sin datos
Jean Fournié	Founder	no data	sin datos	sin datos
Alessandro Moretta	Founder	no data	sin datos	sin datos
Frederic Lombard	Senior VP & CFO	3.2yrs	sin datos	0.014% € 28.8k
Sonia Quaratino	Executive VP	less than a year	sin datos	sin datos
Arvind Sood	Executive VP	less than a year	sin datos	sin datos
Henry Wheeler	Vice President of Investor Relations & Communication	1.4yrs	sin datos	0.0039% € 8.1k
Odile Belzunce	Vice President of Compliance & Operations	5.4yrs	sin datos	0.077% € 157.8k

4.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IDDA se considera experimentado (4.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mario Sznol	Strategic Advisory Board Member	5.6yrs	sin datos	sin datos
Olivier Martinez	Member of Supervisory Board	no data	sin datos	sin datos
Ruslan Medzhitov	Strategic Advisory Board Member	5.6yrs	sin datos	sin datos
Gilles Brisson	Independent Member of Supervisory Board	17yrs	€29.00k	0.090% € 185.2k
Jean-Yves Blay	Independent Member of Supervisory Board	6.5yrs	€29.00k	0.000060% € 123.0
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15yrs	€42.00k	0.031% € 63.6k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.1yrs	€60.00k	0.0012% € 2.5k
Miriam Merad	Chairman of Strategic Advisory Board	5.6yrs	sin datos	sin datos
Veronique Chabernaud	Independent Member of Supervisory Board	9.2yrs	€48.00k	0.00082% € 1.7k
Sebastian Amigorena	Strategic Advisory Board Member	5.6yrs	sin datos	sin datos
Aurelien Marabelle	Strategic Advisory Board Member	5.6yrs	sin datos	sin datos
Tanguy Seiwert	Strategic Advisory Board Member	5.6yrs	sin datos	sin datos

5.6yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de IDDA se considera experimentada (5.4 años de antigüedad promedio).

Innate Pharma Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad